Most independent pharmacies think they know what they are being paid.
They are wrong.
Not because they are careless. Not because they lack intelligence.
Because the system was designed to make the real number invisible until it is too late.
Why this happens
When a Medicare Part D prescription is dispensed, a number appears.
It looks like revenue. It is recorded as revenue. Decisions are made around it.
But that number is not final.
Months later, a reconciliation statement arrives. A portion of that revenue is taken back. The real number was always lower.
This is not an accounting error. It is a mechanism.
What DIR fees actually are
Direct and Indirect Remuneration.
The name sounds technical and minor. It was designed to sound that way.
In 2010, DIR fees were a rounding category. By 2021, they had grown by more than 107,000 percent.
That is not a typo.
What began as a Medicare Part D policy accounting mechanism became the primary tool through which pharmacy benefit managers recovered payments they had already made to pharmacies.
After the fact. Retroactively. Without real-time visibility for the pharmacy being charged.
The cash flow problem this creates
Here is what the pre-2024 cycle looked like.
You dispense a prescription in January. You record the reimbursement as revenue. You make staffing decisions based on that revenue. You make inventory decisions based on that revenue.
In April, a reconciliation statement arrives. The revenue you recorded in January is reduced. The decisions you made in February no longer make sense.
A pharmacist in Nebraska described it this way.
"I had done the math. I felt confident in the numbers. Then the reconciliation came and I realized I had been operating on a fantasy for three months."
That experience is nearly universal among independent owners with significant Part D volume.
What changed in 2024
The Centers for Medicare and Medicaid Services implemented a rule.
Effective January 1, 2024, pharmacy price concessions under Medicare Part D must be reflected at the point of sale.
No more retroactive clawbacks for dispensing events after that date.
This was a genuine policy improvement. It deserved to happen. It did not solve everything.
What the reform did not fix
PBMs had advance notice before the rule took effect.
They used that time to restructure.
Some PBMs embedded what had been a retroactive adjustment into the prospective reimbursement rate. The certainty improved. The rate declined.
Other PBMs moved adjustments into network participation fees, quality tier structures, and credentialing requirements.
Different mechanism. Similar economic effect.
The retroactive clawback is gone. The reimbursement pressure is not.
The error most owners make after the reform
Assuming the problem is solved.
The 2024 rule eliminated one specific mechanism.
It did not eliminate the underlying dynamic.
PBMs still have structural leverage over independent pharmacy reimbursement. The tools changed. The incentives did not.
Owners who stopped auditing their reimbursement position after 2024 are making the same mistake they made before.
Operating on numbers that may not be final.
The reimbursement audit every owner needs
This is not complicated. It is not done often enough.
Step 1 — Locate your PBM contracts
Pull your full PBM contracts for every Part D network you currently participate in.
Not summaries. Not rate sheets. The actual contracts, including all addenda and schedules.
If you cannot locate them within thirty minutes, request them in writing from each PBM network representative today. Keep a record of that request. If a PBM is slow to provide the contracts governing your reimbursement, that reluctance is itself informative.
Step 2 — Map every adjustment mechanism
For contracts covering dispensing events after January 1, 2024, identify the following.
Performance-based adjustments. Quality tier differentials. Network participation fees. Preferred network eligibility criteria.
These are the post-reform equivalents of retroactive DIR fees. They affect your effective reimbursement rate. They need to be understood precisely.
For contracts covering pre-2024 dispensing events, confirm whether retroactive reconciliation obligations are still outstanding. These are real liabilities. They belong on your balance sheet until settled.
Step 3 — Calculate your effective rate by plan
Not by drug. By plan.
Take your total Part D revenue from a specific plan over twelve months. Subtract all fees, adjustments, and participation costs associated with that plan. Divide by your total drug acquisition cost for those same claims.
The resulting margin percentage is the real value of that network relationship.
Most owners who complete this calculation for the first time discover that one or two networks are generating most of their Part D losses. The rest of the business has been subsidizing those relationships without anyone knowing it.
Step 4 — Know where you stand on performance metrics
Your reimbursement tier in the post-reform environment is still partly a function of clinical quality scores.
The categories that matter most across plans are medication adherence rates for diabetic, hypertensive, and cholesterol drug classes; generic dispensing rate; and MTM completion rates.
Most pharmacy management systems can generate reports on your current performance. If yours cannot, your PBM network representative is required to provide that data on request.
Improving your MTM completion rate is one of the most direct levers available for moving your reimbursement tier — and it generates its own separate revenue stream in the process.
Step 5 — Bring the findings to the right people
Your accountant and your buying group representative are the right audience for the analysis you have just produced.
Your primary wholesaler likely has a contract review service or can connect you with one. The cost of that review almost always returns its value if it surfaces even one network participation decision that changes your reimbursement picture.
The principle behind this
You cannot manage a number you cannot see.
That was the fundamental problem with retroactive DIR fees. It remains the fundamental problem with any reimbursement structure that has not been analyzed at the plan level.
The 2024 reform improved transparency at the transaction level.
It did not create transparency at the business level.
That work belongs to the owner.
What reimbursement opacity produces over time
Reimbursement opacity is not neutral.
It produces decisions made on false assumptions.
Staffing levels set against revenue that will be reduced. Capital investments justified by margins that are not real. Network participation continued because exiting feels risky rather than because the math supports staying.
Each of those decisions compounds.
Owners who build their financial practices around verified net reimbursement figures operate from a fundamentally different foundation.
The difference is not sophistication. It is discipline.
What this looks like outside the United States
The DIR fee mechanism belongs specifically to the US Medicare Part D structure.
But the underlying dynamic — reimbursement intermediaries reducing independent pharmacy net payments through opaque, complex mechanisms — is present in every market.
United Kingdom. The NHS Drug Tariff reimbursement calculation for community pharmacies has drawn similar criticism for opacity and inadequacy relative to actual cost pressures. The mechanism is different. The structural tension is identical.
Nigeria. A cash-pay majority market means reimbursement intermediary pressure is less central. The equivalent concern is supply chain markup structures and informal competitive dynamics that compress margins through different but equally real mechanisms.
Canada. Provincial drug benefit programs create varied reimbursement environments with significant variation between provinces. The audit discipline described in this article applies regardless of which provincial system you operate in.
Australia. The PBS dispensing reimbursement environment has been a persistent source of tension between independent pharmacy and government. The effective margin calculation is the same exercise regardless of which dispensing fund it draws from.
Common errors in reimbursement management
Accepting the reconciliation statement without auditing it. Treating average dispensing margin as meaningful without plan-level breakdown. Assuming the 2024 reform resolved the underlying pressure. Not knowing which performance metrics drive your current tier position. Waiting for a financial crisis before completing the audit.
Each error increases exposure. None of them are inevitable.
What to do this week
Two things. Both free. Both available today.
First. Locate your PBM contracts for every Part D network you participate in. If you cannot find them in thirty minutes, request them in writing from each PBM representative today.
Second. Pull your Part D revenue by plan for the last twelve months and begin the effective margin calculation described in Step 3 above.
Even a rough version of that calculation tells you more about your real reimbursement position than most independent owners currently know.
Both actions cost time, not money.
Both change the quality of every financial conversation you have afterward.
Read next on Blinkerhub:
The MTM billing guide covers one of the most direct actions available for improving your reimbursement tier score — while generating its own separate monthly revenue at the same time.
If you are building the case for why revenue outside PBM contracts matters, the physician relationship strategy is the most accessible place to start.
And if the bigger question underneath all of this — whether independent pharmacy is a viable long-term business — is the one that keeps coming back, we have answered it directly.
Blinkerhub is a free weekly intelligence newsletter for independent pharmacy owners worldwide. Not affiliated with any PBM, chain pharmacy, trade association, or pharmacy software vendor. Published every Tuesday at pharmacy.blinkerhub.com.
This article is general business intelligence, not legal, financial, or regulatory advice specific to your pharmacy.